Overview of cardiac markers in heart disease

Clinics in Laboratory Medicine

Volumn 34, Issue 1, 2014, Pages 1-14

  Jarolim, Petr ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute myocardial infarction; Adverse event; Biomarkers; Cardiac markers; Cardiovascular disease; Heart failure; Laboratory medicine; Risk factor

Indexed keywords

ACUTE MYOCARDIAL INFARCTION; ADVERSE EVENT; BIOMARKERS; CARDIAC MARKERS; CARDIOVASCULAR DISEASE; HEART FAILURE; LABORATORY MEDICINE; RISK FACTOR;

BIOLOGICAL MARKERS; DIAGNOSTIC TECHNIQUES, CARDIOVASCULAR; HEART DISEASES; HUMANS;

EID: 84895099043     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2013.11.005     Document Type: Review

References (58)

1. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69(3):89-95.
2. Saenger A.K., Jaffe A.S. Requiem for a heavyweight: the demise of creatine kinase-MB. Circulation 2008, 118(21):2200-2206.
3. Thygesen K., Alpert J.S., Jaffe A.S., et al. Third universal definition of myocardial infarction. Circulation 2012, 126(16):2020-2035.
4. Thygesen K., Alpert J.S., Jaffe A.S., et al. Third universal definition of myocardial infarction. JAm Coll Cardiol 2012, 60(16):1581-1598.
5. Omland T., de Lemos J.A., Sabatine M.S., et al. Asensitive cardiac troponin T assay in stable coronary artery disease. NEngl J Med 2009, 361(26):2538-2547.
6. Saunders J.T., Nambi V., de Lemos J.A., et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation 2011, 123(13):1367-1376.
7. Kleine A.H., Glatz J.F., Van Nieuwenhoven F.A., et al. Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man. Mol Cell Biochem 1992, 116(1-2):155-162.
8. Ishii J., Ozaki Y., Lu J., et al. Prognostic value of serum concentration of heart-type fatty acid- binding protein relative to cardiac troponin T on admission in the early hours of acute coronary syndrome. Clin Chem 2005, 51(8):1397-1404.
9. McCann C.J., Glover B.M., Menown I.B., et al. Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. Eur Heart J 2008, 29(23):2843-2850.
10. Ruff C.T., Bonaca M.P., Kosowsky J.M., et al. Evaluation of the diagnostic performance of heart-type fatty acid binding protein in the BWH-TIMI ED chest pain study. JThromb Thrombolysis 2013, 36(4):361-367.
11. Reichlin T., Hochholzer W., Stelzig C., et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. JAm Coll Cardiol 2009, 54(1):60-68.
12. Potocki M., Reichlin T., Thalmann S., et al. Diagnostic and prognostic impact of copeptin and high-sensitivity cardiac troponin T in patients with pre-existing coronary artery disease and suspected acute myocardial infarction. Heart 2012, 98(7):558-565.
13. BIC-8 results ESC 2013. Available at: Accessed September 17, 2013. http://www.escardio.org/about/press/press-releases/esc13-amsterdam/Pages/hotline-four-bic-8.aspx.
14. Boerrigter G., Costello-Boerrigter L.C., Burnett J.C. Natriuretic peptides in the diagnosis and management of chronic heart failure. Heart Fail Clin 2009, 5(4):501-514.
15. Dos Santos L., Salles T.A., Arruda-Junior D.F., et al. Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure. Circ Heart Fail 2013, 6(5):1029-1038.
16. Gaggin H.K., Mohammed A.A., Bhardwaj A., et al. Heart failure outcomes and benefits of NT- proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study. JCard Fail 2012, 18(8):626-634.
17. Sabatine M.S., Morrow D.A., de Lemos J.A., et al. Evaluation of multiple biomarkers of cardiovascular stress for risk prediction and guiding medical therapy in patients with stable coronary disease. Circulation 2012, 125(2):233-240.
18. Weinberg E.O., Shimpo M., Hurwitz S., et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 2003, 107(5):721-726.
19. Kakkar R., Lee R.T. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008, 7(10):827-840.
20. Kempf T., von Haehling S., Peter T., et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. JAm Coll Cardiol 2007, 50(11):1054-1060.
21. Eggers K.M., Kempf T., Wallentin L., et al. Change in growth differentiation factor 15 concentrations over time independently predicts mortality in community-dwelling elderly individuals. Clin Chem 2013, 59(7):1091-1098.
22. Kitamura K., Kangawa K., Kawamoto M., et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993, 192(2):553-560.
23. Kobayashi K., Kitamura K., Etoh T., et al. Increased plasma adrenomedullin levels in chronic congestive heart failure. Am Heart J 1996, 131(5):994-998.
24. Ridker P.M. High-sensitivity c-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001, 103(13):1813-1818.
25. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. NEngl J Med 2008, 359(21):2195-2207.
26. Koga S., Ikeda S., Yoshida T., et al. Elevated levels of systemic pentraxin 3 are associated with thin-cap fibroatheroma in coronary culprit lesions. JACC Cardiovasc Interv 2013, 6(9):945-954.
27. Lindahl B. Are there really biomarkers of vulnerable plaque?. Clin Chem 2012, 58(1):151-153.
28. Tang W.H., Brennan M.L., Philip K., et al. Plasma myeloperoxidase levels in patients with chronic heart failure. Am J Cardiol 2006, 98(6):796-799.
29. Nicholls S.J., Tang W.H., Brennan D., et al. Risk prediction with serial myeloperoxidase monitoring in patients with acute chest pain. Clin Chem 2011, 57(12):1762-1770.
30. Ho C.Y., López B., Coelho-Filho O.R., et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. NEngl J Med 2010, 363(6):552-563.
31. Zachariah J.P., Colan S.D., Lang P., et al. Circulating matrix metalloproteinases in adolescents with hypertrophic cardiomyopathy and ventricular arrhythmia. Circ Heart Fail 2012, 5(4):462-466.
32. Sharma U.C., Pokharel S., van Brakel T.J., et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110(19):3121-3128.
33. Gullestad L., Ueland T., Kjekshus J., et al. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Am Heart J 2012, 164(6):878-883.
34. Grandin E.W., Jarolim P., Murphy S.A., et al. Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22. Clin Chem 2011, 273:267-273.
35. Hui X., Matsushita K., Sang Y., et al. CKD and Cardiovascular Disease in the Atherosclerosis Risk in Communities (ARIC) Study: interactions with age, sex, and race. Am J Kidney Dis 2013, 62(4):691-702.
36. Akerblom A., Wallentin L., Larsson A., et al. Cystatin C- and creatinine-based estimates of renal function and their value for risk prediction in patients with acute coronary syndrome: results from the PLATelet inhibition and patient Outcomes (PLATO) study. Clin Chem 2013, 59(9):1369-1375.
37. Manzano-Fernández S., Januzzi J.L., Boronat-Garcia M., et al. β-trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure. JAm Coll Cardiol 2011, 57(7):849-858.
38. Kawai K., Kawashima S., Miyazaki T., et al. Serum beta2-microglobulin concentration as a novel marker to distinguish levels of risk in acute heart failure patients. JCardiol 2010, 55(1):99-107.
39. Damman K., Van Veldhuisen D.J., Navis G., et al. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 2010, 96(16):1297-1302.
40. Carlsson A.C., Larsson A., Helmersson-Karlqvist J., et al. Urinary kidney injury molecule 1 and incidence of heart failure in elderly men. Eur J Heart Fail 2013, 15(4):441-446.
41. Jungbauer C.G., Birner C., Jung B., et al. Kidney injury molecule-1 and N-acetyl-ss-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. Eur J Heart Fail 2011, 13(10):1104-1110.
42. Ix J.H., Katz R., Kestenbaum B.R., et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). JAm Coll Cardiol 2012, 60(3):200-207.
43. Kuro-o M., Matsumura Y., Aizawa H., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390(6655):45-51.
44. Kurosu H., Yamamoto M., Clark J.D., et al. Suppression of aging in mice by the hormone Klotho. Science 2005, 309(5742):1829-1833.
45. Arking D.E., Krebsova A., Macek M., et al. Association of human aging with a functional variant of klotho. Proc Natl Acad Sci USA 2002, 99(2):856-861.
46. Arking D.E., Becker D.M., Yanek L.R., et al. KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet 2003, 72(5):1154-1161.
47. Semba R.D., Cappola A.R., Sun K., et al. Plasma klotho and cardiovascular disease in adults. JAm Geriatr Soc 2011, 59(9):1596-1601.
48. Senn T., Hazen S.L., Tang W.H. Translating metabolomics to cardiovascular biomarkers. Prog Cardiovasc Dis 2012, 55(1):70-76.
49. Rhee E.P., Gerszten R.E. Metabolomics and cardiovascular biomarker discovery. Clin Chem 2011, 58(1):139-147.
50. Wang Z., Klipfell E., Bennett B.J., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472(7341):57-63.
51. Tang W.H., Wang Z., Levison B.S., et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. NEngl J Med 2013, 368(17):1575-1584.
52. Koeth R.A., Wang Z., Levison B.S., et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013, 19(5):576-585.
53. Svingen G.F., Ueland P.M., Pedersen E.K., et al. Plasma dimethylglycine and risk of incident acute myocardial infarction in patients with stable angina pectoris. Arterioscler Thromb Vasc Biol 2013, 33(8):2041-2048.
54. Yap I.K., Brown I.J., Chan Q., et al. Metabolome-wide association study identifies multiple biomarkers that discriminate north and south Chinese populations at differing risks of cardiovascular disease: INTERMAP study research articles. JProteome Res 2010, 9(12):6647-6654.
55. Eulalio A., Mano M., Dal Ferro M., et al. Functional screening identifies miRNAs inducing cardiac regeneration. Nature 2012, 492(7429):376-381.
56. Carè A., Catalucci D., Felicetti F., et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007, 13(5):613-618.
57. Callis T.E., Pandya K., Seok H.Y., et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. JClin Invest 2009, 119(9):2772-2786.
58. Bostjancic E., Zidar N., Stajer D., et al. MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. Cardiology 2010, 115(3):163-169.